Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP2D6 Genotype-Guided Tamoxifen Dosing in Indonesian Breast Cancer
NCT05501158Unknown
- Sponsor
- Nalagenetics
- Start
- Jan 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tamoxifen in estrogen receptor-positive breast cancer (ER+) (2 arms), sponsored by Nalagenetics. Primary endpoints: Overall Survival rate at 3 years and Progression Survival rate at 3 years. Status: unknown.
02
Drugs
tamoxifen
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT05501158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501158.